WOBURN, Mass., Aug. 04, 2022 (GLOBE NEWSWIRE) — Biofrontera inc (Nasdaq: BRI) a biopharmaceutical company focused on the commercialization of dermatology products, announces that it will report financial results for the three and six months ended June 30, 2022 ahead of the opening of U.S. financial markets on Friday, August 12, 2022. The Company will host a conference call beginning at 11:00 am Eastern time same day to discuss these results, provide a business update and answer questions.
Information on conference calls and webcasts
| Incident: | Biofrontera Inc. Second Quarter 2022 Financial Results and Business Updates Conference Call |
| Date: | Friday 12 August 2022 |
| time: | 11:00 a.m. Eastern Time |
| telephone conference: | 1-877-877-1275 (US) 1-412-858-5202 (International) |
| web cast: | Live and 90-day replay webcasts are available here and at www.investors.biofrontera-us.com. |
About Biofrontera Inc.
Biofrontera Inc. is a US-based biopharmaceutical company commercializing a portfolio of pharmaceutical products for the treatment of dermatological diseases with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company’s licensed products are used to treat actinic keratoses, which are precancerous skin lesions, and impetigo, a bacterial skin infection. For more information, visit www.biofrontera-us.com.
Contacts
Biofrontera Inc.
Anke to the mills
+1 781 486 1539
[email protected]
LHA Investor Relations
Tirth T. Patel
+1 212 201 6614
[email protected]
###
Comments are closed.